Otros idiomas Coya Therapeutics, Inc.

Acciones

COYA

US22407B1089

Mercado cerrado - Nasdaq Otros sitios de cotización 21:59:30 04/06/2024			Varia. Cinco días.	Varia. 1 de enero.
7,33 ^USD	-2,27 %		-5,66 %	-1,08 %

22/05	Coya Therapeutics anuncia la finalización de un estudio controlado de fase 2 de dosis bajas de interleucina-2 (LD IL-2) en pacientes con enfermedad de Alzheimer	CI
20/05	Coya Therapeutics recibe una inversión en acciones de 5 millones de dólares de la Fundación para el Descubrimiento de Fármacos contra el Alzheimer	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology	03/06
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index	28/05
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients with Alzheimer's disease	23/05
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease	22/05
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease	22/05
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	20/05
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)	20/05
Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation	20/05
Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	17/05
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results	09/05
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	26/04
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit	22/04
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit	18/04
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	08/04
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results	19/03
Coya Therapeutics to Participate in BTIG Fireside Discussion	12/03
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Coya Therapeutics, Inc.

Acciones

COYA

US22407B1089

Otros idiomas

Filtros